Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis

Arthritis Research and Therapy

Volumn 11, Issue 6, 2009, Pages

  Sjöwall, Christopher ^a   Zickert, Agneta ^b   Skogh, Thomas ^a   Wetterö, Jonas ^a   Gunnarsson, Iva ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; CREATININE; CYCLOPHOSPHAMIDE; CYSTATIN C; DOUBLE STRANDED DNA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; ANTINUCLEAR ANTIBODY; AUTOANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CHRONICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG SUBSTITUTION; FEMALE; FLUORESCENCE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; URINALYSIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; BLOOD; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952492445     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2880     Document Type: Article

References (50)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939. 10.1056/NEJMra071297, 18305268.
2. Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US, Munoz LE. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 2008, 8:9-12. 10.1016/j.autrev.2008.07.015, 18703173.
3. Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, Datta SK, Madaio MP. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992, 41:1690-1700. 10.1038/ki.1992.242, 1501424.
4. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643. 10.1002/art.1780330505, 2346519.
5. Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, Kallenberg CG. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997, 56:661-666. 10.1136/ard.56.11.661, 1752296, 9462168.
6. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009, 20:696-704. 10.1681/ASN.2008010112, 19329762.
7. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008, 20:538-544. 10.1016/j.coi.2008.05.004, 18579363.
8. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008, 59:1814-1820. 10.1002/art.24316, 19035410.
9. Sturfelt G, Sjöholm AG. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immun 1984, 75:75-83. 10.1159/000233593.
10. Williams RC, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005, 32:454-461.
11. Enocsson H, Sjöwall C, Skogh T, Eloranta ML, Rönnblom L, Wetterö J. Interferon-α mediates suppression of C-reactive protein: Explanation for muted C-reactive protein response in lupus flares?. Arthritis Rheum 2009, 60:3755-3760. 10.1002/art.25042, 19950271.
12. Sjöwall C, Wetterö J. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clin Chim Acta 2007, 378:13-23. 10.1016/j.cca.2006.12.002, 17239838.
13. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005, 117:104-111. 10.1016/j.clim.2005.08.004, 16214080.
14. Sjöwall C, Wetterö J, Bengtsson T, Askendal A, Almroth G, Skogh T, Tengvall P. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. Biochem Biophys Res Commun 2007, 352:251-258. 10.1016/j.bbrc.2006.11.013, 17113035.
15. Carlucci F, Terence Cook H, Garg A, Pepys MB, Botto M. Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis. Arthritis Rheum 2009, 62:245-249. 10.1002/art.27232, 20039408.
16. Robey FA, Jones KD, Steinberg AD. C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med 1985, 161:1344-1356. 10.1084/jem.161.6.1344, 2187628, 4009117.
17. Bell SA, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998, 113:327-332. 10.1046/j.1365-2249.1998.00655.x, 1905069, 9737658.
18. Minatani M, Aotsuka S, Satoh T. Autoantibodies against C-reactive protein (CRP) in sera of patients with systemic rheumatic diseases. Mod Rheumatol 2001, 11:127-131. 10.1007/s101650170023.
19. Sjöwall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002, 19:155-160. 10.1006/jaut.2002.0608, 12419286.
20. Rosenau BJ, Schur PH. Antibodies to C-reactive protein. Ann Rheum Dis 2006, 65:674-676. 10.1136/ard.2005.037895, 1798154, 16176996.
21. Figueredo MA, Rodriguez A, Ruiz-Yagüe M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, Patiño R. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006, 33:1980-1986.
22. Shoenfeld Y, Szyper-Kravitz M, Witte T, Doria A, Tsutsumi A, Tatsuya A, Dayer JM, Roux-Lombard P, Fontao L, Kallenberg CG, Bijl M, Matthias T, Fraser A, Zandman-Goddard G, Blank M, Gilburd B, Meroni PL. Autoantibodies against protective molecules - C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:227-239. 10.1196/annals.1422.025, 17899624.
23. Augusto JF, Onno C, Blanchard S, Dubuquoi S, Mantovani A, Chevailler A, Jeannin P, Subra JF. Detection of anti-PTX3 autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48:442-444. 10.1093/rheumatology/ken507, 19213851.
24. Bassi N, Zampieri S, Ghirardello A, Tonon M, Zen M, Cozzi F, Doria A. Pentraxins, anti-pentraxin antibodies, and atherosclerosis. Clin Rev Allergy Immunol 2009, 37:36-43. 10.1007/s12016-008-8098-6, 19016000.
25. Mathsson L, Åhlin E, Sjöwall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. Clin Exp Immunol 2007, 147:513-520. 10.1111/j.1365-2249.2006.03313.x, 1810492, 17302901.
26. Sjöwall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004, 6:R87-R94. 10.1186/ar1032, 400426, 15059271.
27. Tan Y, Yu F, Yang H, Chen M, Fang Q, Zhao MH. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008, 69:840-844. 10.1016/j.humimm.2008.09.006, 18852001.
28. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
29. Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol 2008, 4:464-472. 10.1038/ncprheum0896, 18756272.
30. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Diseases 1995, New York:Igaku-Shoin, 2.
31. Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983, 75:382-391. 10.1016/0002-9343(83)90338-8, 6351607.
32. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
33. Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003, 42:1372-1379. 10.1093/rheumatology/keg382, 12810926.
34. Kessel A, Rosner I, Halasz K, Grushko G, Shoenfeld Y, Paran D, Toubi E. Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum 2009, 39:66-70. 10.1016/j.semarthrit.2008.03.003, 18538829.
35. Mogues T, Li J, Coburn J, Kuter DJ. IgG antibodies against bovine serum albumin in humans - their prevalence and response to exposure to bovine serum albumin. J Immunol Methods 2005, 300:1-11. 10.1016/j.jim.2005.01.022, 15890355.
36. Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune depositis and Fcγ receptor type IIA alleles. Arthritis Rheum 2003, 48:460-470. 10.1002/art.10930, 12571856.
37. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, Malmström V, Trollmo C. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122:62-74. 10.1016/j.clim.2006.08.016, 17046329.
38. O'Neill SG, Isenberg DA, Rahman A. Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?. Ann Rheum Dis 2007, 66:989-991. 10.1136/ard.2007.073312, 17626971.
39. Wetterö J, Nilsson L, Jonasson L, Sjöwall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009, 400:128-131. 10.1016/j.cca.2008.10.002, 18973750.
40. Verma S, Szmitko PE, Yeh ET. C-reactive protein: structure affects function. Circulation 2004, 109:1914-1917. 10.1161/01.CIR.0000127085.32999.64, 15117860.
41. Schwedler SB, Guderian F, Dämmrich J, Potempa LA, Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 2003, 18:2300-2307. 10.1093/ndt/gfg407, 14551357.
42. Slevin M, Krupinski J. A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease?. Histol Histopathol 2009, 24:1473-1478.
43. Motie M, Brockmeier S, Potempa LA. Binding of model soluble immune complexes to modified C-reactive protein. J Immunol 1996, 156:4435-4441.
44. Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, Mickle DA, Verma S. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004, 109:833-836. 10.1161/01.CIR.0000117087.27524.0E, 14967730.
45. Mihlan M, Stippa S, Józsi M, Zipfel PF. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ 2009, 16:1630-1640. 10.1038/cdd.2009.103, 19680263.
46. Heuertz RM, Schneider GP, Potempa LA, Webster RO. Native and modified C-reactive protein bind different receptors on human neutrophils. Int J Biochem Cell Biol 2005, 37:320-335. 10.1016/j.biocel.2004.07.002, 15474978.
47. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009, 105:128-137. 10.1161/CIRCRESAHA.108.190611, 19520972.
48. Schwedler SB, Hansen-Hagge T, Reichert M, Schmiedeke D, Schneider R, Galle J, Potempa LA, Wanner C, Filep JG. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin Chem 2009, 55:1728-1731. 10.1373/clinchem.2009.125732, 19617288.
49. Mjelle JE, Rekvig OP, Fenton KA. Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis. Ann Rheum Dis 2007, 66:1661-1668. 10.1136/ard.2007.070482, 17504842.
50. Mjelle JE, Kalaaji M, Rekvig OP. Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZBxNZW)F1 mice. Autoimmunity 2009, 42:104-111. 10.1080/08916930802375729, 19005880.